Genfit stock among the strongest declines in the SBF 120, −33% in one month
Two days after a sharp rebound following the publication of its half-year results, the biotech specialized in liver and metabolic diseases returns to decline. The session unfolds in a Paris market under pressure, weighed down by tensions in French sovereign rates.
A decline that erases part of the previous rebound, against a backdrop of increasing selling pressure
The Genfit stock falls 4.94% to €9.43 in trading, bringing the security back to the lower end of its recent range, in an SBF 120 that declines 1.3%. The decline follows the sharp rebound on Wednesday, itself following the publication of first half 2026 results: Iqirvo royalties had tripled to €21 million, but net loss had widened to €26.1 million. Over one month, the stock is down 33.3%, which concentrates most of the correction occurring since mid-September. The price remains well below the 20-day moving average (€11.60, gap of nearly 19%) and the 50-day moving average (€12.93, gap of more than 27%), testifying to a solidly established downward dynamic over both timeframes.
Only the 200-day moving average, at €9.49, remains within reach: the security is trading slightly below this long-term average, at approximately 0.6% distance. The €8.92 support represents the next notable level in case of continued decline. According to filings consulted, three funds cumulatively hold 2.01% of the capital sold short, up 2.01 percentage points over thirty days. This rapid increase in bearish positions, starting from zero a month ago, suggests growing institutional interest in betting against the stock, even if the absolute magnitude remains modest.
CIC Market Solutions maintains its buy rating with a €20 target despite volatility
CIC Market Solutions confirmed on Thursday its buy rating on Genfit, with an unchanged price target of €20.00. At the current price of €9.43, this target implies an upside potential of approximately 112% compared to current trading levels. The RSI at 36 remains in low territory without reaching the extreme oversold zone, signaling partial exhaustion of selling pressure without clear reversal signal.
Monthly volatility, at 17%, illustrates the amplitude of the stock's swings over recent weeks, between the peaks of the return to markets and strong correction sessions. Over one year, the stock still shows a gain of 188.2%, a legacy of a surge that began in early 2026, although the correction from summer highs has reduced much of this gap. The €8.92 support constitutes the next reference area to watch beyond the 200-day moving average.
